Changes in Apolipoprotein AI after Treatment with High-Dose Medroxyprogesterone Acetate
作者:
N. Crona,
L. Enk,
L.G. Friberg,
G. Samsioe,
G. Silfverstolpe,
期刊:
Gynecologic and Obstetric Investigation
(Karger Available online 1984)
卷期:
Volume 18,
issue 1
页码: 16-20
ISSN:0378-7346
年代: 1984
DOI:10.1159/000299042
出版商: S. Karger AG
关键词: Medroxyprogesterone acetate;Apolipoprotein AI;Endometrial carcinoma
数据来源: Karger
摘要:
21 women (mean age 60 years, range 48–72) were given depot medroxyprogesterone acetate (DMPA), 1,000 mg/week parenterally for 6 months, as part of the treatment for endometrial carcinoma in either clinical stage I or II. Before treatment and after 1, 3 and 6 months of treatment serum apolipoprotein AI was analyzed by electroimmunoassay. There was a significant decrease in apolipoprotein AI after the administration of DMPA, compared to the value before treatment. A low level of apolipoprotein AI is considered a risk factor for the development of atherosclerosis and cardiovascular disease. Such a risk might therefore be anticipated if the period of treatment was extended to several years.
点击下载:
PDF
(1507KB)
返 回